Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) dropped 5.8% during mid-day trading on Thursday. The company traded as low as $40.25 and last traded at $39.7680. Approximately 1,566,017 shares changed hands during trading, a decline of 77% from the average session volume of 6,848,271 shares. The stock had previously closed at $42.23.
Teva Pharmaceutical Industries News Roundup
Here's some of the latest news about TEVA:
- Positive Sentiment: Barclays raised its price target to $50 from $47 and maintained an “Overweight” rating. Argus also reiterated a Buy rating with a $50 target, while HC Wainwright reaffirmed Buy, supporting the positive analyst outlook. Barclays rating information Argus forecast HC Wainwright rating
- Neutral Sentiment: Teva said it reached a settlement in states’ generic-drug price-fixing litigation. The available report does not specify the settlement’s terms or financial impact. Report on settlement
- Negative Sentiment: Executive Vice President of Global R&D and Chief Medical Officer Eric Hughes is leaving for an outside opportunity. David Gardiner will lead the transition as Teva searches for a successor; the leadership change could raise concerns about continuity, though management says R&D priorities and its $6–7 billion innovative-medicines revenue ambition for 2030 are unchanged. Teva R&D leadership announcement
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the stock. Argus lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday. HC Wainwright reiterated a "buy" rating and set a $54.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Tuesday. TD Cowen boosted their target price on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a "buy" rating in a report on Wednesday, November 4th. Oppenheimer increased their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an "outperform" rating in a report on Friday, October 9th. Finally, Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $47.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $48.64.
Read Our Latest Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Performance
The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The stock's 50 day moving average is $40.51 and its two-hundred day moving average is $35.21. The stock has a market cap of $45.54 billion, a price-to-earnings ratio of 90.90, a PEG ratio of 3.69 and a beta of 0.97.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the prior year, the business earned $0.78 EPS. The firm's revenue was down 1.9% compared to the same quarter last year. Analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.
Insider Activity at Teva Pharmaceutical Industries
In related news, insider Brian Savage sold 7,342 shares of the business's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares of the company's stock, valued at approximately $330,225. The trade was a 46.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Richard D. Francis sold 250,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the sale, the chief executive officer owned 927,529 shares of the company's stock, valued at approximately $39,178,824.96. This trade represents a 21.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 715,945 shares of company stock valued at $29,061,351 in the last quarter. 0.54% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Hedge funds and other institutional investors have recently bought and sold shares of the business. Root Financial Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $33,000. Western Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $43,000. Sunbelt Securities Inc. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $45,000. EverSource Wealth Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 64.0% in the first quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company's stock worth $50,000 after acquiring an additional 647 shares during the last quarter. Finally, CX Institutional bought a new position in Teva Pharmaceutical Industries during the second quarter valued at about $54,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.